TAVNEOS

This brand name is authorized in Austria, Croatia, Estonia, France, Ireland, Israel, Italy, Japan, Lithuania, Poland, Spain.

Active ingredients

The drug TAVNEOS contains one active pharmaceutical ingredient (API):

1	Avacopan UNII O880NM097T - AVACOPAN
	Avacopan is a selective antagonist of the human complement 5a receptor (C5aR1 or CD88) and competitively inhibits the interaction between C5aR1 and the anaphylatoxin C5a. The specific and selective blockade of C5aR1 by avacopan reduces the pro-inflammatory effects of C5a, which include neutrophil activation, migration, and adherence to sites of small blood vessel inflammation, vascular endothelial cell retraction and permeability.
	Read more about Avacopan

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
TAVNEOS Hard capsule	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AJ05		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AJ Complement inhibitors
Discover more medicines within L04AJ05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1877261, 1877272
ES	Centro de información online de medicamentos de la AEMPS	1211605002
FR	Base de données publique des médicaments	69292539
IL	מִשְׂרַד הַבְּרִיאוּת	9254
IT	Agenzia del Farmaco	049881016, 049881028
JP	医薬品医療機器総合機構	3999056M1026
LT	Valstybinė vaistų kontrolės tarnyba	1093994, 1093995, 1096003
PL	Rejestru Produktów Leczniczych	100465431
US	FDA, National Drug Code	73556-168